		Application No.	Applicant(s)
Office Action Summary		09/931,402	BROWNING ET AL.
		Examiner	Art Unit
		Christopher H Yaen	1642
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).			
Status			
1)🖂	Responsive to communication(s) filed on <u>21 F</u>	 	
2a)□	,—	s action is non-final.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.			
Disposition of Claims			
4) Claim(s) 7-17,38-49 and 61-70 is/are pending in the application.			
4a) Of the above claim(s) is/are withdrawn from consideration.			
5) Claim(s) is/are allowed.			
6) Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) <u>7-17,38-49 and 61-70</u> are subject to restriction and/or election requirement. Application Papers			
9) The specification is objected to by the Examiner.			
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action. 12)☐ The oath or declaration is objected to by the Examiner.			
Priority under 35 U.S.C. §§ 119 and 120			
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).			
	All b) Some * c) None of:		
1. Certified copies of the priority documents have been received.			
2. Certified copies of the priority documents have been received in Application No			
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 			
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).			
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.			
Attachment(s)			
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)			
2) Notice	of References Cited (F10-692) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Pa	PTO-413) Paper No(s) atent Application (PTO-152)
6 B-11	1		

Application/Control Number: 09/931,402 Page 2

Art Unit: 1642

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 7-17, and 61-70, drawn to a method of treating or reducing neoplasia, classified in class 424, subclass 130.1. Upon election of Group I, Applicants are additionally required to elect a single antibody combination and its corresponding cell line identified by an ATCC number, as indicated above as they apply to group(s). The recited antibodies have different structures one from other and the search for the different combinations would be unduly burdensome. This requirement is not to be construed as a requirement for an election of species, since each of the antibodies recited is not a member of a single genus of invention, but constitutes an independent and patentably distinct invention.
 - II. Claims 38-49, drawn to a pharmaceutical composition, classified in class 530, subclass 387.1. Upon election of Group II, Applicants are additionally required to elect a single antibody combination, as indicated above as they apply to group(s). The recited antibodies have different structures one from other and the search for the different combinations would be unduly burdensome. This requirement is not to be construed as a requirement for an election of species, since each of the antibodies

Application/Control Number: 09/931,402 Page 3

Art Unit: 1642

recited is not a member of a single genus of invention, but constitutes an independent and patentably distinct invention.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the process of treating neoplasia can be accomplished using an antagonist to the LT-β-R, such as organic molecules or through peptide fragments that interact with the receptor.
- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/931,402

Art Unit: 1642

Page 4

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher H Yaen whose telephone number is 703-305-3586. The examiner can normally be reached on Monday-Friday 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196:

Christopher Yaen

Art Unit 1642

February 3, 2003